HANXBIO-B

3378
24.5801.21% ( -0.300 )
Delay Closed: Nov 16, 16:08:00

Overview

HANXBIO-B (3378)

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company’s product pipeline includes HX009, a...

Open
24.040
High
24.600
Low
23.220
Prev. Close
24.880
Volume
68.60K
Turnover
1.62M
Avg Price
23.641
Bid/Ask Ratio
75.00%
Amplitude
5.55%
52wk High
33.800
Volume Ratio
1.32
Turnover Ratio
0.05%
52wk Low
13.480
HK Mkt Cap
3.30B
Market CapHKD
3.30B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-1.13
EPSDynamic
-0.634
EPSStatic
--
BVPS
5.43
P/B
4.52
HK Shares
134.06M
Dividend YieldTTM
--
DividendTTM
--
Shares
134.06M
Min lot size
100
Currency
HKD

Daily Events

  1. Nov, 16

    HanxBio-B staged a rebound from its intraday low, sliding to HK$23.22 before closing at HK$24.58, still down 1.21% on the day; it opened at HK$24.04 below the prior close of HK$24.88, extending the high volatility that included an 8% one-day drop in late October and earlier one-day gains of 13% and 8%, while a HK$486 million warrant financing kept dilution in focus. The AI collaboration with XtalPi on antibody design and drug discovery offered some support. Q2 revenue fell 74.7% year on year to HK$34.65 million, the net loss was HK$21.30 million and EPS was -HK$0.1568, with an operating loss of about HK$30.97 million, leaving fundamentals unresolved. The shares remain below MA20 of HK$26.30 and MA60 of HK$28.05, 27.28% below the 52-week high of HK$33.80 but up 44.08% year to date, though a 4.52x PB and a -21.77x PE leave the price sensitive to R&D progress.

  2. Nov, 10

    HanxBio-B fell 5.35% to HK$25.50, closing at the day's low after an early push to HK$27.60 at 09:39 BJ faded into a one-way slide; volume was just 101,200 shares worth HK$2.72 million, a 0.08% turnover rate. The drop extends a volatile stretch after declines of roughly 6% and 8% in the prior two sessions, with sentiment also weighed by a proposed placing of up to 13.4 million warrants raising about HK$486 million. Q2 2026 revenue fell 74.7% year on year while the net loss widened 6.69% to HK$21.3 million and EPS came in at -HK$0.1568, leaving the stock at 4.69x book with a negative PE. It is still up 49.47% year to date but sits 24.56% below its 52-week high of HK$33.80 and under both the 20-day (HK$26.82) and 60-day (HK$28.35) averages. It did sign a strategic AI drug-discovery framework agreement with XtalPi, though that has not offset dilution and revenue concerns.

  3. Nov, 6

    HanxBio-B reversed from a flat HK$27.84 open and ground lower through the session, touching HK$25.96 in the afternoon before closing at HK$26.14, roughly 6.2% below the prior close of HK$27.86; turnover was just 18,100 shares worth HK$0.475 million at a 0.02% turnover rate, pointing to thin, scattered selling rather than volume-driven exit. The move extends falls of about 8% and 6% over the previous two sessions and leaves the stock 20.1% below its 13 August high of HK$33.80, though still up 58.3% year-to-date, and under both MA20 of HK$27.06 and MA60 of HK$28.53. Fundamentals offer little offset: Q2 2026 revenue was HK$3,465, down 74.7% year on year, with a net loss of HK$21.3 million widening 6.7%, EPS of -HK$0.1568, PE -23.9 and PB 4.97. The XtalPi AI drug-discovery collaboration and a proposed placing of up to 13.4 million warrants raising about HK$486 million have yet to show up in the accounts. Though with a HK$3.62 billion market cap, even small trades can move the tape.

  4. Nov, 5

    Hanxbio-B closed up 5.13% at HK$27.86 — a low-open, one-way grind higher: only 100 shares traded at HK$26.50 in the morning session before afternoon volume carried it to its intraday high of HK$27.86 at the close, with full-day turnover of just HK$274,892 and a 0.010% turnover rate, a thin-liquidity rebound that reads more as repair of the prior session's roughly 8% slide than fresh money. The narrative rests on the AI drug-discovery cooperation with XtalPi and a proposed placing of up to 13.4 million warrants raising about HK$486 million, while fundamentals lag, with Q2 revenue down 74.7% year on year and a HK$21.3 million net loss (HK$0.1568 per share). The stock is still up 63.31% year to date, 106.68% above the 52-week low of HK$13.48, yet at HK$27.86 it sits above the MA20 of HK$27.14 and below the MA60 of HK$28.59, 17.57% off the 52-week high of HK$33.80. Though with a 5.13x price-to-book and a negative P/E, the thin-volume price signal is of limited reliability.

  5. Oct, 28

    Helped by the AI drug-discovery tie-up with XtalPi and the planned warrant placement, the stock opened higher at HK$26.42, spiked to HK$28.82 and eased back to HK$26.44, up 3.69% from the HK$25.50 previous close, though the first two ticks totalled just 300 shares and HK$8,166, so thin liquidity limits how much the move can be read into. The company signed a strategic cooperation framework and a XtalPi Science platform licensing agreement to apply AI for Science to drug discovery, while proposing to place up to 13.4 million warrants at HK$0.36, raising roughly HK$486 million for R&D and working capital. Fundamentals remain at the investment stage: Q2 2026 revenue was HK$34.65 million, down 74.7% year on year, with a net loss of HK$21.3 million. The shares are up 54.98% year to date and 96.14% above the 52-week low of HK$13.48, yet sit below the MA20 of HK$27.61 and MA60 of HK$28.78 and 21.78% under the 13 August high of HK$33.80, while both the cooperation and the placement are still pending.

News